Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer
"We are pleased to be included in these key epilepsy conferences this summer.
- "We are pleased to be included in these key epilepsy conferences this summer.
- LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures.
- Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.
- Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.